Tiffany Le

Tiffany brings over ten years of experience across life sciences investing, M&A, and consulting. She is currently a Principal with NEA, one of the largest and most active venture capital firms in the world. At NEA, she invests in life sciences across medtech, healthtech, and diagnostics. Previously, Tiffany was at Kaiser Permanente Ventures investing across the digital health and life sciences spectrum. Prior to KPV, she was a Senior Consultant with LEK Consulting in their Los Angeles and London offices where she led strategic projects for medtech, biotech, life sciences, and private equity clients spanning M&A, launch and commercialization strategy, and product and geographic expansion projects.

Tiffany has also collaborated on research leveraging brain organoid and synthetic biology models to interrogate Alzheimer’s Disease, and has had prior experience at GE Ventures and Amgen. She currently observes on the Boards of or works with Allay Therapeutics, Moximed, Norm, Revelle Aesthetics, Setpoint Medical, and Willow. Tiffany received a BA in Business Economic Theory from the University of California, Los Angeles and an MBA from Harvard Business School.